GeneDx Holdings Corp.

NasdaqGS:WGS Rapporto sulle azioni

Cap. di mercato: US$2.2b

GeneDx Holdings Gestione

Gestione criteri di controllo 3/4

GeneDx Holdings Il CEO è Katherine Stueland, nominato in May2022, e ha un mandato di 2.5 anni. la retribuzione annua totale è $ 3.58M, composta da 18.9% di stipendio e 81.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.22% delle azioni della società, per un valore di $ 4.83M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.1 anni e 3.3 anni.

Informazioni chiave

Katherine Stueland

Amministratore delegato

US$3.6m

Compenso totale

Percentuale dello stipendio del CEO18.9%
Mandato del CEO2.5yrs
Proprietà del CEO0.2%
Durata media del management1.1yrs
Durata media del Consiglio di amministrazione3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce

Nov 23
GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is Still On The Mark Following 40% Share Price Bounce

US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

Nov 01
US$76.67 - That's What Analysts Think GeneDx Holdings Corp. (NASDAQ:WGS) Is Worth After These Results

GeneDx Holdings: Phenomenal Gains, More Upside Potential In Medium Term

Oct 30

GeneDx Holdings: Stock To Keep Outperforming As Business Momentum Persists

Oct 21

After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Oct 04
After Leaping 53% GeneDx Holdings Corp. (NASDAQ:WGS) Shares Are Not Flying Under The Radar

Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

Aug 29
Is GeneDx Holdings (NASDAQ:WGS) Using Debt Sensibly?

GeneDx Holdings: Profits On The Horizon For AI Driven Health Platform

Aug 19

Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

Jul 27
Market Participants Recognise GeneDx Holdings Corp.'s (NASDAQ:WGS) Revenues Pushing Shares 28% Higher

GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

Jun 12
GeneDx Holdings Corp.'s (NASDAQ:WGS) 30% Jump Shows Its Popularity With Investors

GeneDx Holdings: Mapping A Path To Leadership In Pediatric Genetic Testing

Jun 06

Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

Apr 24
Further Upside For GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Introduce Price Risks After 42% Bounce

GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

Feb 23
GeneDx Holdings Corp. (NASDAQ:WGS) Released Earnings Last Week And Analysts Lifted Their Price Target To US$9.13

The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Feb 22
The Market Lifts GeneDx Holdings Corp. (NASDAQ:WGS) Shares 107% But It Can Do More

Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Dec 20
Improved Revenues Required Before GeneDx Holdings Corp. (NASDAQ:WGS) Stock's 56% Jump Looks Justified

Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Nov 02
Analyst Forecasts Just Became More Bearish On GeneDx Holdings Corp. (NASDAQ:WGS)

Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Nov 01
Not Many Are Piling Into GeneDx Holdings Corp. (NASDAQ:WGS) Stock Yet As It Plummets 49%

Sema4 names Kevin Feeley as CFO

Aug 26

Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Aug 20
Things Look Grim For Sema4 Holdings Corp. (NASDAQ:SMFR) After Today's Downgrade

Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 19
Sema4 Holdings Corp. (NASDAQ:SMFR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Sema4 Q2 2022 Earnings Preview

Aug 12

Sema4 Holdings, Big Data For Precision Medicine Solutions

Jul 18

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Katherine Stueland rispetto agli utili di GeneDx Holdings?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$83m

Jun 30 2024n/an/a

-US$117m

Mar 31 2024n/an/a

-US$135m

Dec 31 2023US$4mUS$675k

-US$176m

Sep 30 2023n/an/a

-US$459m

Jun 30 2023n/an/a

-US$494m

Mar 31 2023n/an/a

-US$533m

Dec 31 2022US$12mUS$454k

-US$549m

Compensazione vs Mercato: La retribuzione totale di Katherine ($USD 3.58M ) è inferiore alla media delle aziende di dimensioni simili nel mercato US ($USD 5.54M ).

Compensazione vs guadagni: La retribuzione di Katherine è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Katherine Stueland (48 yo)

2.5yrs

Mandato

US$3,575,335

Compensazione

Ms. Katherine A. Stueland serves as Chief Executive Officer & Director at GeneDx Holdings Corp. (formerly known as Sema4 Holdings Corp.) since May 2022 and serves as its President. She served as President...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Katherine Stueland
President2.5yrsUS$3.58m0.22%
$ 4.8m
Kevin Feeley
Chief Financial Officer2.3yrsUS$1.57m0.16%
$ 3.6m
Karen Ponchner
Head of Operations1.1yrsNessun datoNessun dato
Eric Olivares
Chief Product & Technology Officerless than a yearNessun datoNessun dato
Jami Biliboaca
Head of People Strategyless than a yearNessun datoNessun dato
Paul Kruszka
Chief Medical Officer2.5yrsNessun datoNessun dato
Melanie Duquette
Chief Growth Officer1.2yrsNessun datoNessun dato
Sabrina Dunbar
Chief of Staffno dataNessun datoNessun dato
Britt Johnson
Head of Medical Affairsless than a yearNessun datoNessun dato

1.1yrs

Durata media

Gestione esperta: Il team dirigenziale di WGS non è considerato esperto (durata media 1.1 anni), il che suggerisce un nuovo team.


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Katherine Stueland
President2.5yrsUS$3.58m0.22%
$ 4.8m
Joshua Ruch
Independent Director7yrsUS$162.00k0.71%
$ 15.6m
Richard Pfenniger
Director2.6yrsUS$147.00k0.10%
$ 2.2m
Keith Meister
Independent Director2.8yrsUS$162.00k0.026%
$ 579.8k
Eli Casdin
Independent Director4.3yrsUS$154.50k0.028%
$ 610.9k
Jason Ryan
Chairman of the Board3.3yrsUS$992.46k0.53%
$ 11.7m
Emily Leproust
Independent Director4.2yrsUS$160.75k0.030%
$ 671.9k

3.3yrs

Durata media

50.5yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di WGS sono considerati esperti (durata media dell'incarico 3.3 anni).